NextCure (NASDAQ:NXTC – Get Free Report)‘s stock had its “buy” rating reaffirmed by stock analysts at HC Wainwright in a report released on Friday, Benzinga reports. They currently have a $8.00 price target on the stock. HC Wainwright’s target price would suggest a potential upside of 422.88% from the company’s previous close. Separately, Needham & […]